Ann: Opthea announces A$80m Capital raise, page-31

I am new to the forum but thought i would weigh in. I find it a little hard to be tough on management about the costs/delays. They go hand in hand and are largely out of management control in clinical trials, in my experience with these companies. I agree it does seem like a horrifying amount but I think its a combination of inflation (which has been multiple in the medical space) and mostly delays. I think they are doing the best they can using the caryle agreement. It looks like this drug will take something like $US500m to get it from phase 1 through phase 3....wow its a expensive business.

But we need to look at the potential reward. Amy competitor will have to spend the same amount to get here. I havent seen anyone mention the blinded look at the data they mentioned which highlighted better results so far in Phase 3 than pHase 2 which I would have thought was the big news in the announcement. The 2 trials are massive and slow but once confirmed and in place will be very hard to unseat,,,they have gone the high cost road but the rewards could match.

you are not wrong about a further raise next year but company is obviously hoping conditions will have improved by then. I wouldnt bet on it but it is what it is......